Patients’ experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation
Background Globally, 56.8 million people are living with hepatitis C and over three-quarters of those reside in low and middle-income countries (LMICs). Barriers and enablers to hepatitis C care among people who inject drugs in high-income countries are well documented. However, there is scant literature describing the patient experience in LMICs. Understanding the barriers and enablers to care from the patient perspective is important to inform service refinements to improve accessibility and acceptability of hepatitis C care. Methods We conducted a qualitative evaluation of the patient experience of accessing the national hepatitis C program at eight hospital sites in Myanmar. Semi-structured interviews were conducted with four to five participants per site. Interview data were analysed thematically, with deductive codes from Levesque et al.’s (2013) Framework on patient-centred access to healthcare. Results Across the eight sites, 38 participants who had completed treatment were interviewed. Barriers to accessing care were mostly related to attending for care and included travel time and costs, multiple appointments, and wait times. Some participants described how they did not receive adequate information on hepatitis C, particularly its transmission routes, and on the level of cirrhosis of their liver and what they were required to do after treatment (i.e. reduce alcohol consumption, liver cirrhosis monitoring). Many participants commented that they had few or no opportunities to ask questions. Provision of treatment at no cost was essential to accessibility, and gratitude for free treatment led to high acceptability of care, even when accessing care was inconvenient. Conclusions These findings highlight the importance of streamlining and decentralising health services, adequate human resourcing and training, and affordable treatment in maximising the accessibility and acceptability of hepatitis C care in LMICs. Findings from this work will inform future service delivery refinements for national program and other decentralised programs to improve accessibility and acceptability of hepatitis C care in Myanmar..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC health services research - 24(2024), 1 vom: 16. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Draper, Bridget [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Barriers |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12913-023-10456-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054411564 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054411564 | ||
| 003 | DE-627 | ||
| 005 | 20240117064658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12913-023-10456-0 |2 doi | |
| 035 | |a (DE-627)SPR054411564 | ||
| 035 | |a (SPR)s12913-023-10456-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Draper, Bridget |e verfasserin |0 (orcid)0000-0003-2624-2510 |4 aut | |
| 245 | 1 | 0 | |a Patients’ experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Globally, 56.8 million people are living with hepatitis C and over three-quarters of those reside in low and middle-income countries (LMICs). Barriers and enablers to hepatitis C care among people who inject drugs in high-income countries are well documented. However, there is scant literature describing the patient experience in LMICs. Understanding the barriers and enablers to care from the patient perspective is important to inform service refinements to improve accessibility and acceptability of hepatitis C care. Methods We conducted a qualitative evaluation of the patient experience of accessing the national hepatitis C program at eight hospital sites in Myanmar. Semi-structured interviews were conducted with four to five participants per site. Interview data were analysed thematically, with deductive codes from Levesque et al.’s (2013) Framework on patient-centred access to healthcare. Results Across the eight sites, 38 participants who had completed treatment were interviewed. Barriers to accessing care were mostly related to attending for care and included travel time and costs, multiple appointments, and wait times. Some participants described how they did not receive adequate information on hepatitis C, particularly its transmission routes, and on the level of cirrhosis of their liver and what they were required to do after treatment (i.e. reduce alcohol consumption, liver cirrhosis monitoring). Many participants commented that they had few or no opportunities to ask questions. Provision of treatment at no cost was essential to accessibility, and gratitude for free treatment led to high acceptability of care, even when accessing care was inconvenient. Conclusions These findings highlight the importance of streamlining and decentralising health services, adequate human resourcing and training, and affordable treatment in maximising the accessibility and acceptability of hepatitis C care in LMICs. Findings from this work will inform future service delivery refinements for national program and other decentralised programs to improve accessibility and acceptability of hepatitis C care in Myanmar. | ||
| 650 | 4 | |a Patient experience |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Barriers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Enablers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatitis C |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hospital |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a National program |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Low and middle-income countries |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Myanmar |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Yee, Win Lei |4 aut | |
| 700 | 1 | |a Bowring, Anna |4 aut | |
| 700 | 1 | |a Naing, Win |4 aut | |
| 700 | 1 | |a Kyi, Khin Pyone |4 aut | |
| 700 | 1 | |a Htay, Hla |4 aut | |
| 700 | 1 | |a Howell, Jessica |4 aut | |
| 700 | 1 | |a Hellard, Margaret |4 aut | |
| 700 | 1 | |a Pedrana, Alisa |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC health services research |d London : BioMed Central, 2001 |g 24(2024), 1 vom: 16. Jan. |w (DE-627)SPR028228308 |w (DE-600)2050434-2 |x 1472-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:16 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12913-023-10456-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 16 |c 01 | ||